Menu
- Home
+ - Publications
+
- Archives
+
- BCIQ
+
- Conferences
+
- eLearning
+
- Follow Us
Latest News
4:34 PM Nov 20, 2018
Deal with Idorsia gives Santhera shot at second DMD candidate
In a deal that will make Idorsia Ltd. (SIX:IDIA) its largest shareholder, Santhera Pharmaceuticals Holding...
3:46 PM Nov 20, 2018
ICER to review peanut allergy therapies from Aimmune, DBV
The Institute for Clinical and Economic Review (ICER) will review peanut allergy therapies AR101 from...
3:35 PM Nov 20, 2018
Merck KGaA, Palantir team up to drive cancer research data sharing and integration
Merck KGaA (Xetra:MRK) and big data company Palantir Technologies (Palo Alto, Calif.) plan to create a JV...
2:28 PM Nov 20, 2018
FDA planning class-wide cancer companion diagnostic guidance
FDA plans to release guidance soon that will make it easier to get a cancer companion diagnostic approved...
2:05 PM Nov 20, 2018
Ascletis adds marketed HBV drug from Roche to Chinese portfolio
With one marketed HCV therapy in China and another under review, Ascletis Pharma Inc. (HKSE:1672) extended...
1:26 PM Nov 20, 2018
Sanders, Khanna propose compulsory licensing to reduce U.S. drug prices
Sen. Bernie Sanders (I-Vt.) announced Tuesday plans to introduce legislation that would impose compulsory...
12:57 PM Nov 20, 2018
Pear, Sandoz launch first FDA-approved digital therapeutic
Pear Therapeutics Inc. (Boston, Mass.) and Sandoz launched reSET, the first FDA-authorized prescription...
12:53 PM Nov 20, 2018
On heels of Sobi deal, Novimmune's emapalumab gets FDA approval
FDA approved Gamifant emapalumab-lzsg from Novimmune S.A. (Plan-les-Ouates, Switzerland), giving Novimmune...
11:44 AM Nov 20, 2018
U.K.'s MHRA to seek new CEO as Hudson steps down next fall
Ian Hudson said he will step down in September 2019 as CEO of the U.K.'s Medicines and Healthcare products...
11:13 AM Nov 20, 2018
REMS prep pushes back Sage's Zulresso timeline
Sage Therapeutics Inc. (NASDAQ:SAGE) anticipates a June 2019 launch of postpartum depression candidate...
3:06 AM Nov 20, 2018
Leo Pharma invests in PellePharm to develop rare skin disease therapy
Dermatology company Leo Pharma A/S (Ballerup, Denmark) gained an option to acquire PellePharm Inc. (Menlo...
4:53 PM Nov 19, 2018
Bavencio fails Phase III for ovarian cancer
Hopes for Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) to get ahead in the ovarian cancer space,...
4:39 PM Nov 19, 2018
Aimmune down on safety concerns for peanut allergy therapy
Aimmune Therapeutics Inc. (NASDAQ:AIMT) was off $3.33 (11%) to $26.29 on Monday after the New England...
3:52 PM Nov 19, 2018
Pediatric IBD workshop calls for innovative trial design
Participants at an FDA-sponsored workshop called on regulators and drug developers to minimize placebo...
3:44 PM Nov 19, 2018
Management tracks: Brickell, Genevant
Dermatology company Brickell Biotech Inc. (Boulder, Colo.) hired Robert Brown as CEO, effective Jan. 1. He...
3:15 PM Nov 19, 2018
Immunocore, Genentech team up to bring soluble TCR therapy into clinic
Despite losing at least five key executives this year, Immunocore Ltd. (Abingdon, U.K.) has teamed up with...
2:17 PM Nov 19, 2018
U.K. groups push for explicit language on medicines regulation post-Brexit
U.K. health and pharma groups are asking their country and the EU to explicitly make cooperation on...
12:22 PM Nov 19, 2018
Inflazome to bring inflammasome inhibitors to clinic with €40M series B
Inflazome Ltd. (Dublin, Ireland) raised €40 million ($45.7 million) in a series B round Monday, giving...
12:17 PM Nov 19, 2018
RNAi method targets placenta directly to treat preeclampsia
In a Nature Biotechnology study, researchers from University of Massachusetts Medical School and...
11:20 AM Nov 19, 2018
NASH company Genfit planning U.S. listing
As it prepares for a readout from a Phase III study of its lead candidate to treat non-alcoholic...
About Biocentury
Contact
Support
Products & Solutions
Legal
- Follow Us
What is BioCentury?
BioCentury employs a fully integrated multimedia platform — including publications, video, online data solutions and conferences — to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the financial markets.